Beyond the Elite: Lower-Ranked Universities Outpace Top Schools in Key Industry Research Partnerships

As billions of dollars in federal biomedical research support hang in the balance, a new analysis from the Cure Innovation Index suggests that American universities may be overlooking one of their most accessible sources of research funding: industry partnerships. The analysis, presented at the University-Industry Demonstration Partnership annual conference, UIDP Denver 2026, finds that industry today provides only about 3 to 8 percent of research funding for the 243 universities ranked as the best in the United States for translational science. That modest figure stands in sharp contrast to the scale of the funding challenge now facing academic research, and it points to substantial untapped capacity for collaboration between universities and the pharmaceutical, biotech, and medical technology companies that depend on academic science for their pipelines.

The fiscal backdrop gives the findings particular urgency. The FY2027 President’s Budget Request proposed cutting the National Institutes of Health by 12 percent, roughly $5 billion, and reducing the National Science Foundation by more than half, alongside a 15 percent cap on NIH indirect cost rates, a figure far below the 50 to 60 percent rates most research universities negotiate. With final FY2027 appropriations deferred until after the midterm elections, science agencies are operating on a stopgap basis, leaving institutions uncertain about their federal funding outlook. Against that uncertainty, the Cure analysis offers a data-driven map of how universities can diversify, and it arrives with a genuinely surprising conclusion: there is no single blueprint for successful industry engagement.

The analysis identified four distinct pathways through which universities engage industry: scientific collaboration, industry-sponsored clinical research, small-business partnerships, and entrepreneurial training. On the first two pathways, the expected hierarchy holds, and the highest-ranked universities lead. Top-decile institutions publish papers with industry collaborators at rates more than twice those of bottom-decile universities, with 8.9 percent of publications at top-decile schools involving industry co-authors compared with 3.5 percent at bottom-decile institutions. Leading universities also attract higher levels of industry participation in clinical trials, with industry-sponsored trials accounting for 24.5 percent of trial activity among top-decile universities versus 19.0 percent among bottom-decile institutions. Notably, that clinical trial gap is far narrower than the co-authorship gap, an early indication that industry engagement is not confined to elite institutions.

On the other two pathways, the conventional ranking story reverses entirely. Through the federal Small Business Technology Transfer program, bottom-decile universities earn STTR awards at a rate of 0.82 per $10 million in research funding, against 0.18 for top-decile institutions, a rate more than four times higher. Data from the National Science Foundation’s Innovation Corps program show a similar inversion: while top-ranked universities are more likely to participate in I-Corps overall, lower-ranked universities earn I-Corps awards at more than five times the rate per research dollar, 0.83 versus 0.15 per $10 million. In practical terms, institutions outside the traditional research elite are building commercialization engines through entrepreneurship and small-business collaboration at a pace that their better-funded peers have not matched.

The scale of the divergence is striking when expressed in absolute terms. Bottom-decile institutions form small-business research partnerships at more than four times the rate of top-decile universities per research dollar, and they earn federal entrepreneurship-training awards at more than five times the rate. Perhaps the most dramatic individual example is the University of Texas Health Science Center at Tyler, ranked 184th overall on the Cure Innovation Index. That institution runs nearly nine out of every 10 of its clinical trials with an industry partner, about three and a half times the rate of the top-ranked decile, working across 13 pharmaceutical and biotech partners with a portfolio concentrated in oncology and hematology. Its performance illustrates the central finding of the analysis: meaningful industry engagement can emerge far beyond the universities that traditionally dominate discussions about research excellence and innovation.

Standout performers appear at every tier of the rankings, and the analysis suggests they follow recognizably different models. The University of California, San Diego, ranked seventh, and the University of Pennsylvania, ranked third, exemplify what might be called the elite research partnership model, combining strong overall performance with deep industry engagement through scientific collaboration and industry-sponsored clinical research. UC San Diego recorded industry co-authorship at 11.1 percent of publications and industry sponsorship on 30.2 percent of its 543 assessed trials, while Penn posted 8.8 percent co-authorship and 23.3 percent industry sponsorship across 754 trials. Both institutions demonstrate that the traditional strengths of flagship research universities translate directly into industry appeal for large-scale scientific and clinical collaboration.

A different model emerges among mid-ranked institutions that have invested heavily in entrepreneurial infrastructure. The University of Connecticut, ranked 99th, and the University of Georgia, ranked 118th, outperform many higher-ranked peers in industry-facing entrepreneurial activity and small-business partnerships. UConn earned STTR awards at a rate of 0.64 per $10 million in research funding and recorded industry sponsorship on 24.7 percent of its 81 assessed trials, while Georgia posted an STTR rate of 0.66 per $10 million. Both figures substantially exceed the rates achieved by top-decile universities, showing that commercialization strength is not limited to the highest-ranked research universities and that deliberate investment in technology transfer and startup support can yield measurable industry engagement even without an elite research portfolio.

The implications run in both directions. For pharmaceutical, biotech, and other industry organizations seeking university partners, the analysis suggests that institutional reputation alone is a poor proxy for fit. Seema Kumar, CEO of Cure, the healthcare innovation ecosystem headquartered in New York City, noted that a company seeking large-scale clinical research may find its best fit at a university with an affiliated medical center, while one looking for entrepreneurial partnerships may find stronger opportunities at an institution with deep startup and technology-transfer support. In other words, the optimal partner depends on the objective, and the data now exist to make that match systematically rather than by reputation.

For universities themselves, Kumar emphasized that the analysis offers an equally important lesson: there is no single path to successful industry engagement. Institutions can build meaningful partnerships by leaning into their particular strengths rather than trying to replicate a single model borrowed from the most famous research universities. A specialized health science center in East Texas and a flagship land-grant university in Georgia are demonstrating that focused strategies, whether concentrated clinical trial operations in oncology or aggressive pursuit of small-business technology transfer awards, can generate industry revenue and research opportunities that partially insulate institutions from federal funding volatility. What surprised the Cure team, Kumar said, is that some universities excel in clinical research and scientific collaboration while others build powerful commercialization engines through entrepreneurship, and in some cases institutions outside the traditional elite may have lessons to teach the rest of the sector.

The analytical foundation behind these findings is itself notable. The Cure Innovation Index, launched in April 2026, evaluates 25 indicators across three core domains: Research Capabilities, Entrepreneurial Readiness, and Market Translation. It ranks the top 303 academic institutions, comprising 243 universities and 60 institutes and centers, from a field of more than 6,000 nationwide, and provides peer-benchmarked comparisons along with customized improvement recommendations. The methodology integrates validated data from more than a dozen federal and commercial databases, including the National Science Foundation’s Higher Education Research and Development Survey and Dimensions, an interlinked research information system provided by Digital Science. By normalizing partnership metrics against institutional research funding, the index reveals patterns of engagement that raw dollar figures would obscure, and it is precisely those normalized comparisons that expose the unexpected strength of lower-ranked institutions. As federal appropriations remain unresolved and universities confront the prospect of sustained funding pressure, the analysis suggests that the most resilient institutions of the coming decade may be those that treat industry not as a supplementary revenue stream but as a structural partner, and that discover, as the data show, that the door to such partnership is open far wider than the rankings imply.

Subject of Research: University-industry research partnerships as an alternative funding pathway for U.S. biomedical research institutions

Article Title: Industry partnerships offer new opportunities for universities amid federal funding pressures

Article References: Industry partnerships offer new opportunities for universities amid federal funding pressures. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: university-industry partnerships, biomedical research funding, Cure Innovation Index, NIH budget cuts, clinical trials, STTR program, I-Corps, technology transfer, translational science, entrepreneurship, research universities, pharmaceutical industry